IBIO

SEC source: 0001104659-23-075015 · tm2319771-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,578

F1 · kind: Consists of 75,833 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 75,833 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan") that expired prior to vesting.

SEC source: 0001104659-23-073578 · tm2319412d1_4seq1.xml · nonDerivative · entry 3

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,411

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

SEC source: 0001104659-23-073578 · tm2319412d1_4seq1.xml · nonDerivative · entry 2

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,511

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

SEC source: 0001104659-23-073578 · tm2319412d1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,736

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

SEC source: 0001104659-23-063805 · tm2316530-1_4seq1.xml · nonDerivative · entry 2

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257,595

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

SEC source: 0001104659-23-063805 · tm2316530-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257,619

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

SEC source: 0001104659-23-048952 · tm2313583-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 261,777

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.1815 to $1.2 inclusive. The Reporting Person undertakes to provide to the Issuer, any securities holder of the Issuer, or the staff of the Securities and Exchange Commission, upon report, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-23-040819 · tm2311232-2_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 266,159

F1 · kind: Consists of 50,000 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 50,000 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 50,000 RSUs vest pro rata quarterly over 12 months beginning April 1, 2023.

F1 · shares: Consists of 50,000 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 50,000 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 50,000 RSUs vest pro rata quarterly over 12 months beginning April 1, 2023.

SEC source: 0001104659-23-040818 · tm2311232-1_4seq1.xml · nonDerivative · entry 1

Duran Felipe · CIK 0001964267 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,633

F1 · kind: Consists of 37,500 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 37,500 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 37,500 RSUs vest pro rata quarterly over 12 months beginning April 1, 2023.

F1 · shares: Consists of 37,500 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 37,500 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 37,500 RSUs vest pro rata quarterly over 12 months beginning April 1, 2023.

SEC source: 0001104659-23-037424 · tm2310726-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,159

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.1303 to $2.1315 inclusive. The Reporting Person undertakes to provide to the Issuer, any securities holder of the Issuer, or the staff of the Securities and Exchange Commission, upon report, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-23-024785 · tm237675-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,372

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

SEC source: 0001104659-23-006184 · tm234222-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · Interim CEO and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,348

F1 · security: Consists of 130,000 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 130,000 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 130,000 RSUs vest pro rata over a twelve- month period, such vesting to terminate if Dr. Brenner is no longer the Company's Interim Chief Executive Officer.

F1 · shares: Consists of 130,000 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 130,000 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 130,000 RSUs vest pro rata over a twelve- month period, such vesting to terminate if Dr. Brenner is no longer the Company's Interim Chief Executive Officer.

SEC source: 0001104659-22-118976 · tm2230588-1_4seq1.xml · nonDerivative · entry 1

Brenner Martin · CIK 0001770235 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,348

F1 · shares: Consists of 95,348 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 95,348 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 95,348 RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Corporation's 2023 objectives, as defined by the Board of Directors.

SEC source: 0001104659-22-118975 · tm2230588-2_4seq1.xml · nonDerivative · entry 1

Lutz Robert Matthew · CIK 0001786203 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,165

F1 · shares: Consists of 100,057 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 100,057 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 100,057 RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Corporation's 2023 objectives, as defined by the Board of Directors.

SEC source: 0001104659-22-099236 · tm2225675d1_4.xml · derivative · entry 1

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Stock · 2,000,000 shares

Expires 2032-09-07

F1 · security: These options vest ratably in equal monthly instalments over a 36-month period beginning on the date of the grant (September 8, 2022), subject to the conditions of the iBio, Inc. 2020 Omnibus Incentive Compensation Plan, as amended, and the related stock option grant agreement.

F1 · derivative.exercise_date: These options vest ratably in equal monthly instalments over a 36-month period beginning on the date of the grant (September 8, 2022), subject to the conditions of the iBio, Inc. 2020 Omnibus Incentive Compensation Plan, as amended, and the related stock option grant agreement.

SEC source: 0001104659-22-096528 · tm2224840-1_4seq1.xml · derivative · entry 1

Brenner Martin · CIK 0001770235 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2032-08-29

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

SEC source: 0001104659-22-096529 · tm2224840-2_4seq1.xml · derivative · entry 1

Lutz Robert Matthew · CIK 0001786203 · See Remark

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2032-08-28

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

SEC source: 0001104659-22-033320 · tm229111-2_4seq1.xml · nonDerivative · entry 1

Lutz Robert Matthew · CIK 0001786203 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,375

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F1 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3410 to $0.3481 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-149215 · tm2135158-5_4seq1.xml · derivative · entry 1

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,000

Underlying: Common Stock · 109,000 shares

Expires 2031-12-08

F1 · security: These options vest pro rata on a monthly basis over 12 months.

F1 · shares: These options vest pro rata on a monthly basis over 12 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months.

SEC source: 0001104659-21-149220 · tm2135158-4_4seq1.xml · derivative · entry 1

GENERAL HILL (Ret) JAMES T. · CIK 0001441718 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,000

Underlying: Common Stock · 109,000 shares

Expires 2031-12-08

F1 · security: These options vest pro rata on a monthly basis over 12 months.

F1 · shares: These options vest pro rata on a monthly basis over 12 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months.

SEC source: 0001104659-21-149239 · tm2135158-8_4seq1.xml · derivative · entry 1

Clark William D · CIK 0001355415 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,000

Underlying: Common Stock · 109,000 shares

Expires 2031-12-08

F1 · security: These options vest pro rata on a monthly basis over 12 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months.

SEC source: 0001104659-21-149236 · tm2135158-2_4seq1.xml · derivative · entry 1

Schimmelpennink Evert B. · CIK 0001713795 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,000

Underlying: Common Stock · 109,000 shares

Expires 2031-12-08

F1 · security: These options vest pro rata on a monthly basis over 12 months.

F1 · shares: These options vest pro rata on a monthly basis over 12 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months.

SEC source: 0001104659-21-149234 · tm2135158-1_4seq1.xml · derivative · entry 1

Kropotova Alexandra · CIK 0001825323 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,000

Underlying: Common Stock · 109,000 shares

Expires 2031-12-08

F1 · security: These options vest pro rata on a monthly basis over 12 months.

F1 · shares: These options vest pro rata on a monthly basis over 12 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months.

SEC source: 0001104659-21-149231 · tm2135158-7_4seq1.xml · derivative · entry 1

Armstrong Linda Washington · CIK 0001825579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,000

Underlying: Common Stock · 109,000 shares

Expires 2031-12-08

F1 · security: These options vest pro rata on a monthly basis over 12 months.

F1 · shares: These options vest pro rata on a monthly basis over 12 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months.

SEC source: 0001104659-21-149222 · tm2135158-3_4seq1.xml · derivative · entry 1

Sender Gary · CIK 0001659085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,000

Underlying: Common Stock · 109,000 shares

Expires 2031-12-08

F1 · security: These options vest pro rata on a monthly basis over 12 months.

F1 · shares: These options vest pro rata on a monthly basis over 12 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months.

SEC source: 0001104659-21-149211 · tm2135158-6_4seq1.xml · derivative · entry 1

Chang Glenn · CIK 0001384967 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,000

Underlying: Common Stock · 109,000 shares

Expires 2031-12-08

F1 · security: These options vest pro rata on a monthly basis over 12 months.

F1 · shares: These options vest pro rata on a monthly basis over 12 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months.

SEC source: 0001104659-22-033319 · tm229111-1_4seq1.xml · nonDerivative · entry 1

Maddux Randy Joe · CIK 0001683826 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,757

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc.

F2 · price: These shares were sold in a single transaction at a price of $0.6832 per share.

SEC source: 0001104659-21-119847 · tm2128467-1_4seq1.xml · derivative · entry 1

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Stock · 2,000,000 shares

Expires 2031-09-22

F1 · security: These options vest as follows: (1) 25% of options granted will vest one year following the grant date; and (2) after one year following the grant date, 6.25% of the options granted will vest for each additional three (3) months of employment, subject to the conditions of the iBio, Inc. 2020 Omnibus Incentive Plan, as amended and the stock option grant agreement.

F1 · derivative.exercise_date: These options vest as follows: (1) 25% of options granted will vest one year following the grant date; and (2) after one year following the grant date, 6.25% of the options granted will vest for each additional three (3) months of employment, subject to the conditions of the iBio, Inc. 2020 Omnibus Incentive Plan, as amended and the stock option grant agreement.

SEC source: 0001104659-21-109469 · tm2125787-3_4seq1.xml · derivative · entry 1

Maddux Randy Joe · CIK 0001683826 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2031-08-22

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

SEC source: 0001104659-21-109468 · tm2125787-2_4seq1.xml · derivative · entry 1

Brenner Martin · CIK 0001770235 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2031-08-22

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

SEC source: 0001104659-21-109470 · tm2125787-4_4seq1.xml · derivative · entry 1

Lutz Robert Matthew · CIK 0001786203 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2031-08-22

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

SEC source: 0001104659-21-109467 · tm2125787-1_4seq1.xml · derivative · entry 1

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Stock · 2,000,000 shares

Expires 2031-08-22

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.

SEC source: 0001104659-21-109466 · tm2125787d5_4seq1.xml · derivative · entry 1

Clark William D · CIK 0001355415 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-08-22

F1 · security: These options vest pro rata on a monthly basis over 36 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 36 months.

SEC source: 0001104659-21-078869 · tm2119289d1_4.xml · derivative · entry 1

Schimmelpennink Evert B. · CIK 0001713795 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-06-06

F1 · shares: These options vest pro rata on a monthly basis over 36 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 36 months.

SEC source: 0001104659-21-061237 · tm2115085d1_4.xml · derivative · entry 1

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000,000

Underlying: Common Stock · 3,000,000 shares

Expires 2031-04-29

F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three (3) months of employment.

F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three (3) months of employment.

SEC source: 0001104659-21-032333 · tm218800d2_4seq1.xml · derivative · entry 2

Lutz Robert Matthew · CIK 0001786203 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2031-03-04

F2 · derivative.exercise_date: The stock option vests as follows: (1) 25% of the options granted will vest after one year of employment with the Company; and (2) after one year of employment with the Company, 6.25% of the options granted will vest for each additional three (3) months of employment, subject to the conditions of the 2020 Plan and the stock option grant agreement.

SEC source: 0001104659-21-032333 · tm218800d2_4seq1.xml · nonDerivative · entry 1

Lutz Robert Matthew · CIK 0001786203 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,000

F1 · shares: Each restricted stock unit represents a contingent right to receive one share of common stock of iBio, Inc. (the "Company"). The restricted stock units vest in three equal annual installments beginning March 4, 2022, subject to the conditions of the iBio, Inc. 2020 Omnibus Equity Incentive Plan (the "2020 Plan") and the restricted stock unit grant agreement.

SEC source: 0001104659-21-005499 · tm213570d2_4.xml · derivative · entry 1

Brenner Martin · CIK 0001770235 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2031-01-18

SEC source: 0001104659-20-131634 · tm2037478d2_4.xml · derivative · entry 2

Maddux Randy Joe · CIK 0001683826 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 465,000

Underlying: Common Stock · 465,000 shares

Expires 2030-11-30

F2 · derivative.exercise_date: The options vest as follows: (i) 25% of the options granted under the 2018 Plan will vest after one year of employment with the Company; and (ii) after one year of employment with the Company, 6.25% of the options granted will vest for each additional three (3) months of employment.

SEC source: 0001104659-20-131634 · tm2037478d2_4.xml · nonDerivative · entry 1

Maddux Randy Joe · CIK 0001683826 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,000

F1 · shares: Consists of 309,000 shares of iBio, Inc. (the "Company") common stock , $0.001 par value per share (the "Common Stock") represented by 309,000 restricted stock units ("RSUs") granted under the Company's 2018 Omnibus Equity Incentive Plan, as amended (the "2018 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 309,000 RSUs start vesting pro rata on the (i) first anniversary of the grant date; (ii) second anniversary of the grant date; and (iii) third anniversary of the grant date.

SEC source: 0001104659-20-115459 · tm2033244d6_form4.xml · derivative · entry 1

Armstrong Linda Washington · CIK 0001825579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-10-13

F1 · shares: These options vest pro rata on a monthly basis over 36 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 36 months.

SEC source: 0001104659-20-115457 · tm2033244d5_form4.xml · derivative · entry 1

Kropotova Alexandra · CIK 0001825323 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-10-13

F1 · shares: These options vest pro rata on a monthly basis over 36 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 36 months.

SEC source: 0001104659-20-115456 · tm2033244d4_form4.xml · derivative · entry 1

Sender Gary · CIK 0001659085 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-10-13

F1 · shares: These options vest pro rata on a monthly basis over 36 months.

F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 36 months.

SEC source: 0001408408-20-000047 · ownership.xml · nonDerivative · entry 4

Eastern Capital LTD · CIK 0001408408 · 10% owner

Portfolio Services Ltd. · CIK 0001488856 · 10% owner

DART KENNETH BRYAN · CIK 0001331271 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,629,693

F4 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $2.69 to $3.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request

F4 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $2.69 to $3.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request

SEC source: 0001408408-20-000047 · ownership.xml · nonDerivative · entry 3

Eastern Capital LTD · CIK 0001408408 · 10% owner

Portfolio Services Ltd. · CIK 0001488856 · 10% owner

DART KENNETH BRYAN · CIK 0001331271 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,494,129

F3 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.65 to $4.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

F3 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.65 to $4.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

SEC source: 0001408408-20-000047 · ownership.xml · derivative · entry 5

Eastern Capital LTD · CIK 0001408408 · 10% owner

Portfolio Services Ltd. · CIK 0001488856 · 10% owner

DART KENNETH BRYAN · CIK 0001331271 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,925,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.

F1 · kind: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.

F1 · price: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.

F1 · derivative.exercise_date: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.

F1 · derivative.expiration_date: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.

SEC source: 0001408408-20-000047 · ownership.xml · nonDerivative · entry 2

Eastern Capital LTD · CIK 0001408408 · 10% owner

Portfolio Services Ltd. · CIK 0001488856 · 10% owner

DART KENNETH BRYAN · CIK 0001331271 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,758,993

F2 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.62 to $4.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

F2 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.62 to $4.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

SEC source: 0001408408-20-000047 · ownership.xml · nonDerivative · entry 1

Eastern Capital LTD · CIK 0001408408 · 10% owner

Portfolio Services Ltd. · CIK 0001488856 · 10% owner

DART KENNETH BRYAN · CIK 0001331271 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,114,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.

F1 · kind: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.

F1 · price: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.

SEC source: 0001408408-20-000039 · ownership.xml · nonDerivative · entry 3

Eastern Capital LTD · CIK 0001408408 · 10% owner

Portfolio Services Ltd. · CIK 0001488856 · 10% owner

DART KENNETH BRYAN · CIK 0001331271 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,114,597

F3 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.05 to $4.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

F3 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.05 to $4.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

SEC source: 0001408408-20-000039 · ownership.xml · nonDerivative · entry 2

Eastern Capital LTD · CIK 0001408408 · 10% owner

Portfolio Services Ltd. · CIK 0001488856 · 10% owner

DART KENNETH BRYAN · CIK 0001331271 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,882,734

F2 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.36 to $4.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

F2 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.36 to $4.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.